Form 4: Immuneering Director Thomas Schall Increases Stake with Significant Stock Purchase

Immuneering Corp. Director Thomas J. Schall has acquired 40,485 shares of Class A Common Stock at a weighted average price of $2.2052 per share, increasing his beneficial ownership to 43,385 shares.

Summary

• Thomas J. Schall, a Director of Immuneering Corp. (IMRX), purchased 40,485 shares of the company's Class A Common Stock.
• The transaction occurred on June 17, 2025, at a weighted average price of $2.2052 per share.
• The purchase price for the shares ranged from $2.16 to $2.24 per share.
• Following this transaction, Mr. Schall beneficially owns a total of 43,385 shares of Immuneering Corp. Class A Common Stock.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 8

Explanation: A director's significant stock purchase typically signals strong insider confidence in the company's prospects, which is a positive indicator for investors.

Positives

• A significant purchase by a company director, Thomas J. Schall, indicates confidence in the company's future prospects and valuation.
• The acquisition of 40,485 shares substantially increases the director's direct beneficial ownership in the company, aligning his interests more closely with shareholders.

Related Party Transactions

• The transaction involves a director of Immuneering Corp. purchasing shares of the company, which is a related party transaction and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive sign of confidence from the company's leadership, potentially influencing investor sentiment and stock price positively.

Key Dates

Recommendation

Keywords

Immuneering Corp, IMRX, Thomas J. Schall, Insider Purchase, SEC Form 4, Stock Acquisition, Director Stock Purchase, Equity Investment, Rule 10b5-1